Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 8/20 | 0.68 |
| ▸ | GRM5 | P41594 | 7/20 | 0.60 |
| ▸ | MEN1 | O00255 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | GBA1 | P04062 | 5/20 | 0.57 |
| ▸ | NPC1 | O15118 | 5/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.55 |
| ▸ | TP53 | P04637 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30485981 | 1.00 | RAB9A (0.68) | RAB9AGRM5MEN1KMT2AGBA1 | |
| SCHEMBL921576 | 0.89 | L3MBTL1 (0.54) | RAB9AMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL1021638 | 0.84 | RAB9A (0.66) | RAB9AGRM5MEN1KMT2AGBA1 | |
| SCHEMBL13489802 | 0.82 | ADORA1 (0.48) | RAB9AMEN1KMT2ASMN1; SMN2POLB | |
| SCHEMBL19718960 | 0.82 | ADORA1 (0.48) | RAB9AMEN1KMT2ANPC1SMN1; SMN2 | |
| SCHEMBL3119185 | 0.81 | RAB9A (0.78) | RAB9AGRM5MEN1KMT2AGBA1 | |
| SCHEMBL31725239 | 0.81 | RAB9A (0.78) | RAB9AGRM5MEN1KMT2AGBA1 | |
| SCHEMBL14353530 | 0.81 | RAB9A (1.00) | RAB9AGRM5MEN1KMT2AGBA1 | |
| SCHEMBL968790 | 0.81 | GRM5 (0.51) | RAB9AGRM5MEN1KMT2AGBA1 | |
| SCHEMBL3211414 | 0.81 | XIAP (0.59) | RAB9AGRM5MEN1KMT2ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111349121-A | Cobalt carbonyl complex and preparation method thereof | 中国人民解放军国防科技大学 | 2020-06-30 | — | — | CN | claimed |
| CN-116462661-A | Deuterated 3- (pyridin-4-yl) propionic acid compound, and preparation method and medical application thereof | 深圳信立泰药业股份有限公司 | 2023-07-21 | — | — | CN | disclosed |
| WO-2021001350-A1 | 2,2-DIMETHYL-N-[6-(1-METHYL-PIPERIDIN-4-CARBONYL)-PYRIDIN-2-YL]-PROPIONAMIDE, METHOD FOR PREPARING (6-AMINO-PYRIDIN-2-YL)-(1-METHYL-PIPERIDIN-4-YL)-METHANONE USING SAID COMPOUND, AND USE OF SAID COMPOUND IN THE PREPARATION OF LASMIDITAN | MOEHS IBERICA, S.L. (ES) | 2021-01-07 | — | — | WO | disclosed |
| CN-111349121-A | Cobalt carbonyl complex and preparation method thereof | 中国人民解放军国防科技大学 | 2020-06-30 | — | — | CN | disclosed |
| US-9963462-B2 | Sepiapterin reductase inhibitors | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2018-05-08 | — | — | US | disclosed |
| EP-3031799-B1 | AROMATIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2018-04-04 | — | — | EP | disclosed |
| US-9776962-B2 | Aromatic compounds with GPR40 agonistic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-03 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (DE) | 2017-04-06 | — | — | US | disclosed |
| EP-3031799-A1 | AROMATIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2016-06-15 | — | — | EP | disclosed |
| EP-1303483-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002016318-A1 | NOVEL THIOUREA DERIVATIVES AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | PACIFIC CORPORATION (KR) | 2002-02-28 | — | — | WO | disclosed |
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | MOORMAN ALAN E (US) | 2001-11-29 | — | — | US | disclosed |
| US-5945425-A | ADENOSINE TRIPHOSPHASE INHIBITOR; DNA VIRICIDE | G.D. SEARLE & CO. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5716964-A | BRAIN DISORDERS; ANTIISCHEMIC AGENTS | G.D. SEARLE & CO. (US) | 1998-02-10 | — | — | US | disclosed |
| WO-1995029897-A1 | METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS | G.D. SEARLE & CO. (US) | 1995-11-09 | — | — | WO | disclosed |
| EP-0436831-A2 | Imidazo[1,2-a]pyridinylalkyl compounds for treatment of neurotoxic injury | G.D. Searle & Co. (US) | 1991-07-17 | — | — | EP | disclosed |
| WO-1991008211-A1 | IMIDAZO[1,2-a]PYRIDINYLALKYL COMPOUNDS FOR TREATMENT OF NEUROTOXIC INJURY | G.D. SEARLE & CO. (US) | 1991-06-13 | — | — | WO | disclosed |
| US-4772619-A | ANTIULCER AGENTS | G. D. SEARLE & CO. (US) | 1988-09-20 | — | — | US | disclosed |
| US-4687775-A | ANTIULCER AGENTS | G. D. SEARLE & CO. (US) | 1987-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010047038-A1 | Method of using (H+/K+) ATPase inhibitors as antiviral agents | ATP4A, ATP1A1, ATP1A4 | RAB9A 486/4885GRM5 4551/4885MEN1 4836/4885 |
| US-20170096435-A1 | SEPIAPTERIN REDUCTASE INHIBITORS | SPR, QDPR, SRR | RAB9A 4069/4885GRM5 1220/4885MEN1 4876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.